If you have been reading about NR1D2 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
A May 2021 teaching guide did not feature statements on adverse reactions, precautions and contraindications, while materials in November 2021 and April 2022 were unbalanced and promotional in nature, and consideration was not given to the appropriateness of hiring a trainer to carry out consultations with patients during a pilot training course. That same year, U.S. District Judge Karen Marston issued the first substantive rulings in the multidistrict litigation, dismissing several claims while allowing core allegations - including claims that the manufacturers failed to warn about gastrointestinal risks - to proceed. At that stage, the litigation encompassed more than 2,600 individual lawsuits involving Ozempic, Mounjaro, and related GLP-1 receptor agonist drugs.
Tyrosinase is a highly conserved protein in animals and apparently arose already in bacteria. The tyrosinase related protein (Tyrp1) and dopachrome tautomerase (Dtc), which encode for protein implicated in melanin synthesis which are the common regulatory elements of exon/intron structure. The development of the three types of vertebrate pigment cells, although different, thus converge at a certain point to allow the expression of members of the tyrosinase family, in order to produce melanin pigments. Tyrosinase family related genes plays an important role in the evolution, genetics, and developmental biology of pigment cells, as well as to approach human disorders associated with defects in their synthesis, regulation or function in vertebrates three types of melanin producing pigment cells are well known since embryonic origin i.e., from the neural crest, neural tube and pineal body. All of them have the capacity to produce melanin pigments. Their biosynthesis is governed by evolutionary conserved enzymes of the tyrosinase family( tyr, tyr1 and tyr2) also called DOPAchrome tautomerase (dct). Among them Tyr plays significance role in melanin production. However, sequenced genome from the different taxa for evolutionary analysis in the depth become more crucial in present study. Similarly, the type-3 copper protein family perform various biological function including pigment formation, innate immunity and oxygen transport.
The tree is an acceptable source of forage or fodder for animals, providing vital protein and other nutrients. It does well in the dry season and in drought, while providing life saving food for local livestock and animals. Cows, goats and sheep eat the pods and leaves. There seems to be evidence that Mimosa tenuiflora forage or fodder cause development defects to pregnant ruminants in Brazil. The tree is an important source of forage for bees, especially during the dry season and in the beginning of the wet season. Like most plants in the family Fabaceae, Mimosa tenuiflora fertilizes the soil via nitrogen fixing bacteria. The tree is useful in fighting soil erosion and for reforestation. Mimosa tenuiflora is a very good source of fuel wood and works very well for making posts, most likely because of its high tannin content (16%), which protects it from rot. Due to its high tannin content, the bark of the tree is widely used as a natural dye and in leather production. It is used to make bridges, buildings, fences, furniture and wheels. It is an excellent source of charcoal and at least one study has been done to see why this is the case. The healing properties of the tree make it useful in treating domestic animals. A solution of the leaves or bark can also be used for washing animals in the prevention of parasites. Because the tree keeps most of its leaves during the dry season, it is an important source of shade for animals and plants during that time.
Sources: en.wikipedia.org
==== Infrastructure ==== The conflict resulted in widespread destruction in Lebanon that was particularly seen in the south, east, and Dahieh—the southern suburbs of the capital, Beirut. According to the World Bank, 99,209 houses were damaged during the conflict, of which 18% were destroyed. By 31 October 2024, nearly 25% of the buildings in towns near the border were damaged or destroyed, with the most destruction occurring in Kfar Kila and Ayta ash-Shaab. Roughly 80% of the damage occurred after 2 October. In the areas that the IDF had captured during its ground invasion into Lebanon, 42% of buildings were destroyed, according to NBC News. Amnesty International reported the damaging or destruction of over 10,000 buildings between October 2024 and January 2025, with 70% of the buildings in Yaroun, Dhayra, and Al-Bustan being severely damaged or destroyed. UN-Habitat reported that 27% of buildings in Marjayoun and 15% of buildings in Bint Jbeil were damaged or destroyed, while the mayor of Kfar Kila stated that 90% of the homes in the village were destroyed during the conflict, with the remaining 10% sustaining damage. The scale of destruction in Dahieh was comparable to the 2006 Lebanon war, with 353 buildings in the area being destroyed and more than 6,000 houses damaged. The Hezbollah-linked newspaper Al Akhbar reported that the cost of damages in Dahieh was $630 million. More than 60 schools have been destroyed since September 2024, according to Save the Children.
==== Synroc ==== The Australian Synroc (synthetic rock) is a more sophisticated way to immobilize such waste, and this process may eventually come into commercial use for civil wastes (it is currently being developed for U.S. military wastes). Synroc was invented by Ted Ringwood, a geochemist at the Australian National University. The Synroc contains pyrochlore and cryptomelane type minerals. The original form of Synroc (Synroc C) was designed for the liquid high-level waste (PUREX raffinate) from a light-water reactor. The main minerals in this Synroc are hollandite (BaAl2Ti6O16), zirconolite (CaZrTi2O7) and perovskite (CaTiO3). The zirconolite and perovskite are hosts for the actinides. The strontium and barium will be fixed in the perovskite. The caesium will be fixed in the hollandite. A Synroc waste treatment facility began construction in 2018 at ANSTO.
Colin Edwards Interviews and Papers about Dylan Thomas, National Library of Wales "Papers of Colin Edwards (d. 1994), a radio journalist of Welsh descent, relating to his incomplete book on Dylan Thomas ('Dylan Remembered')" Dylan Thomas Collection at Harry Ransom Center University of Texas Dylan Thomas Digital Collection at Harry Ransom Center University of Texas & University of Swansea Dylan Thomas Digital Collection from the University at Buffalo Libraries "Archival material relating to Dylan Thomas". UK National Archives. Websites
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.